Sector News

Novartis loses top oncology executive Strigini to retirement

December 21, 2017
Life sciences

As Novartis preps for its upcoming CEO transition, so too will it have to find a new leader in oncology. One of the drugmaker’s top executives, Bruno Strigini, is retiring for personal reasons, Novartis announced Friday.

Strigini joined Novartis in 2014 after spending several years at Merck, ultimately as president of the company’s European and Canadian operations. During his time at the Swiss drug giant, Strigini managed the integration GlaxoSmithKline’s oncology programs following a massive asset swap and saw the company through its blockbuster patent loss for Gleevec last year. He additionally helped Novartis beat all competitors to an FDA nod for CAR-T treatment Kymriah.

Novartis didn’t give any indication how it plans to fill the role, saying only that it will “announce his successor in due time.” He’ll come off of the executive committee by the end of the year and fully hand off the reins in early 2018.

Just before Strigini joined Novartis, the company agreed to its massive asset swap with GSK, offloading its vaccine programs—besides flu—in exchange for Glaxo’s cancer offerings. Outgoing Novartis CEO Joe Jimenez called the deal “transformational” when it was announced as it would ultimately propel the drugmaker to a leadership position in oncology.

Much more recently, Novartis won the industry’s first CAR-T approval in August, when the FDA backed Kymriah to treat children and young adults with a rare form of acute lymphoblastic leukemia. CAR-T meds are re-engineered T cells collected from each patient and infused back into the patient to identify and attack cancer, and some experts see them as a future cornerstone of cancer treatment.

Interestingly, Novartis hired Strigini as head of oncology development and medical affairs to replace Alessandro Riva, who was in the post on an interim basis. Riva has since left Novartis for Gilead and played a key role in that company’s pursuit and purchase of Kite Pharma, another top CAR-T player. After the buyout closed, Gilead promoted Riva to executive vice president of oncology therapeutics.

Now, Gilead and Novartis are the only two commercial CAR-T companies, with many others pursuing the technology in the clinic.

Strigini saw another shakeup at Novartis last year when the company divided its drug group into two units—pharmaceuticals and oncology—and put him in charge of the cancer outfit. At the time, Novartis touted Strigini as being “instrumental in the successful integration of the oncology assets acquired from GSK.”

Outgoing Novartis CEO Joe Jimenez reiterated the point in Friday’s announcement, saying Strigini “has navigated the business unit through the Gleevec patent expiration and has led the successful integration of the GSK Oncology Product Portfolio acquired in 2015.”

“I wish him the best for his future,” Jimenez added.

Prior to Merck, Strigini served as president, international for UCB and as a VP of international marketing for GlaxoSmithKline, according to his LinkedIn page.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).